Response Scientific®, Inc. is a growth stage company that has developed a patented microencapsulation technology named Aegis Fluidics™ that "shields and protects" the contents of our microcapsules including Rx drugs, Rx medical foods, and nutraceuticals in liquid form, from damaging stomach acids and enzymatic degradation. Protein and peptide derived drugs and nutraceuticals are particularly subject to this damage.

1. RESPONSE SCIENTIFIC, INC. (RSI)
is a biotechnology company founded in May 2002.
RSI's mission is to improve people's lives
through innovative research leading to revolutionary
new healthcare treatments.
5 Independence Way – Suite 300
Princeton, New Jersey 08540
Contact Gregg Webster, CEO
Tel 609-945-4913
gwebster@responsescientific.com
©2012 RSI

2. RSI has assembled a stellar scientific advisory board
and personnel to accomplish our mission and address
the global health concerns of millions of people.
Chairman: Emmanuel C. Opara, PhD.
Wake Forest University Medical School
Institute for Regenerative Medicine
Winston-Salem, North Carolina
©2012 RSI Page 2

3. Response Scientific’s focus is twofold:
1) Introduce our patented insulin resistance treatment, Receptorex INS2*,
prescription-only medical food to market.
2) Introduce our patented Aegis Fluidics Microencapsulation™ technology
that protects and shields encapsulated drugs, nutraceuticals, Probiotics, and
medical foods from damaging stomach acids and enzymatic degradation
*Code Name
©2012 RSI Page 3

4. Type 1 and Type 2 Diabetes Discovery
Insulin Resistance Treatment
RSI's insulin resistance small molecule prescription medical food
formulation Receptorex INS2* is comprised of liquid GRAS components
which reduce ROS imbalance, thereby enhancing insulin sensitivity and
lowering the amount of insulin required to maintain targeted blood glucose
levels.
*Code Name
©2012 RSI Page 4

5. RSI plans to bring this patented prescription medical food
to market in 1Q 2013.
Receptorex INS2* has demonstrated the ability to repair or sensitize
damaged insulin receptors and lower the amount of insulin required to
maintain healthy blood glucose levels by up to 50%.
Applies to both Type 1 and Type 2 Diabetes patients.
Receptorex INS2* may also delay or even prevent Pre-Diabetes
patients from advancing to full-blown diabetes.
No prescription medication exists today that reduces the amount of
exogenous insulin without increasing blood glucose levels.
*Code Name
©2012 RSI Page 5

6. Receptorex INS2* may also benefit sufferers of Alzheimer’s disease
and PCOS (polycystic ovarian syndrome) as insulin resistance
directly affects both of these disease states.
In 2006 researchers at Brown University coined the term Type 3
Diabetes after discovering the insulin resistance link to Alzheimer's.
PCOS is currently treated with Metformin, a diabetes medication. It is
important to note that Receptorex INS2* will be the first medication to
utilize our newly developed Aegis Fluidics™ Microencapsulation
drug delivery technology.
*Code Name
©2012 RSI Page 6

7. Wholly-Owned Subsidiary of Response Scientific, Inc.
Aegis Fluidics™ is the sales and marketing arm of RSI’s patented
microfluidics encapsulation device and technology.
Hogan Lovells, our patent attorneys, advise that certain products
manufactured utilizing our technology may qualify for new patents.
Developed and Patented by
North Carolina State University and Biocell Technologies
Exclusive Worldwide Licensee: Response Scientific, Inc.
©2012 RSI Page 7

8. Bioavailability Breakthrough
Superior Delivery To Bloodstream
Aegis Microfluidics capsules Deliver Contents By
Diffusion*
The Aegis Microcapsules travel through the stomach to the small intestines virtually unharmed
by stomach acids or enzymatic actions. Diffusion of the contents of the microcapsules begins upon
entry to the small intestines and continues through the digestive tract releasing contents along the way.
Approximately 60% of the contents are emptied in the first 60 minutes.
Diffusion and Concentration Gradients
The passage of the microcapsules through the intestines is dependent on the concentration gradients.
A concentration gradient exists whenever a concentrated solution is in contact with a less concentrated solution.
Because the solutions are in contact, particles may flow between the two solutions by the process known as
diffusion. Diffusion is a term used to describe the mixing of two different substances that are placed in contact.
Diffusion is the migrating of these different particles. Although particles move in every direction, there is a net flow
from the more concentrated solution to the less concentrated solution. As the number of particles in the more
concentrated solution diminishes and the number of particles in the less concentrated increases, the difference
in concentration between the two solutions decreases. Hence, the concentration gradient is said to get smaller. All
else being equal, the concentrations of the solutions change more rapidly when the difference in their concentrations
is greater.
This diffusion process continues until the concentrations of the two solutions are equal. This state is known as dynamic
equilibrium. When the two solutions are in dynamic equilibrium, particles continue to move between the
two solutions, but there is no net flow in any one direction.
While in transit through the digestive tract the Aegis Fluidics Microcapsules never reach equilibrium
and therefore continue to empty their contents until the contents are exhausted.
* See drawing next page
Page 8

9. Page 9

10. The patented Aegis Fluidics device allows for the mass production of
Prescription Drugs, Prescription Medical Foods & Nutraceuticals.
The resulting microcapsules
are time-released, acid resistant,
and not digestible by enzymes,
thus shielding the components from
both acid and enzymatic degradation.
©2012 RSI Page 10

11. Bioavailability is the amount of a drug that enters the bloodstream.
Drugs are considered to have good or poor bioavailability.
The Aegis Fluidics™ technology increases bioavailability
allowing lower amounts of ingredients to produce the
performance of higher amounts of ingredients.
In light of the economies of scale, the cost savings to major
manufacturers of drugs, nutraceuticals and medical foods
are expected to be substantial.
©2012 RSI Page 11

12. Scalability
The Aegis Fluidics™ device is easily scalable,
from small testing or sample production
to large mass production volumes for market.
In 2012 RSI will begin to sublicense
this technology to pharmaceutical manufacturers.
©2012 RSI Page 12

13. CANADIAN TEST MARKET
The Canadian population is 31,280 million or 10% of the US
10% benchmark is used by Canadian companies wanting to do business
in the US as an estimate of the total business potential.
75% of Canadians live in urban areas. Large urban areas in Canada are:
Toronto, Montreal, Ottawa, Vancouver, Edmonton, Calgary, SW Ontario,
and the province of Quebec.
Canadian urban centers Toronto and Vancouver contain an ever growing
Asian population. Asian countries hold tremendous potential.
90% of Canadians live within 100 miles of the US border and are familiar
with US shopping habits, presenting a favorable advantage for marketing
dollars.
The eastern provinces of Nova Scotia, New Brunswick and Prince Edward
Island are considered as having markets and cultures similar to the US.
©2012 RSI Page 13

14. CANADIAN TEST MARKET
Retail Stores
The total Canadian retail market in terms of dollars per year
is $260 billion (multiply x 10 for the US).
Drugs and medicine represent 13.3 billion dollars.
Food sales (grocery stores) count for 59 billion.
Supermarkets count for 55 billion in sales.
Canadian retailers pay their bills within 30 days.
©2012 RSI Page 14

15. CANADIAN TEST MARKET
Manufacturing
The best location for a Canadian manufacturing facility is along the
Ontario 401 highway corridor. The 401 runs from Windsor, Ontario
(close to Detroit US) to Ottawa.
The 401 is Canada's busiest highway. A manufacturing location
located along the 401 corridor is essential in order to take
advantage of the best distribution options available and service the
highly populated area of southwestern Ontario. The head offices of
most
of Canada's retailers are located in Toronto.
The US is Canada's largest trading partner and the Canadian dollar
has been trading on par for the last few months and it is expected
to do so for the next few years. This is an important factor for
US companies doing business in Canada.
©2012 RSI Page 15

16. 5 Independence Way – Suite 300, Princeton, New Jersey 08540
Contact Gregg Webster, CEO
Tel 609-945-4913
gwebster@responsescientific.com